Tudo é um!

Interessante...
Ainda não vi oncologistas recomendando controle glicêmico como parte de tratament/prevenção de tumores!
Os convites para que pacientes irresponsivos entrem em trials internacionais no entanto...

In September 2010, AICR published “The Diabetes-Cancer Connection” paper discussing the research on the link between these two diseases and how health professionals can counsel patients on lifestyle changes to lower risk of both.
Now several studies in the Journal of Clinical Oncology show how both type 2 diabetes and insulin resistance negatively impact prognosis in breast cancer patients. Those with type 2 diabetes or insulin resistance do not fare as well as breast cancer patients who did not have those conditions.
An accompanying editorial discusses two simple procedures that health care providers should do for patients with breast cancer to improve outcomes.
1.            Measure waist circumference. This simple measure may point to metabolic syndrome associated with type 2 diabetes and related risk factors.
2.            Measure HOMA index (indicator of insulin resistance).
The authors of the editorial explain that with these measures, health care providers would be able to individualize a patient’s treatment to include diet and physical activity programs that are known to improve survival for many.
The editors give a call to action to integrate care of these two diseases:
“The time has come to overcome the conventional tunnel vision that results in two diseases being treated by separate clinicians, and to move towards a comprehensive approach that ideally integrates oncologists, internists, nutritionists, and other health care professionals in an attempt to improve breast cancer prognosis in a significant proportion of patients.”